Veritable’s Gain Therapeutics GANX Stock Holding History

Veritable’s Portfolio GANX Stock Details GANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-25,064	Closed	-$103K	–	930
2022 Q1	$103K	Hold	25,064	–	–	﹤0.01%	890
2021 Q4	$136K	Hold	25,064	–	–	﹤0.01%	890
2021 Q3	$187K	Buy	+25,064	New	+$209K	﹤0.01%	853

Other funds holding GANX

Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return

Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Veritable's GANX Position: Q2 2022 in Review

Veritable sold out of Gain Therapeutics (GANX) in Q2 2022, closing a stake of 25,064 shares — an estimated $103K sold.

Veritable first reported a position in GANX in Q3 2021 and held it in 3 quarters. The position peaked at $187K in Q3 2021. 16 funds tracked by Wall St. Rank hold GANX as of Q2 2022.

Veritable reported no remaining Gain Therapeutics position as of Q2 2022 after selling out during the quarter.
Veritable sold 25,064 Gain Therapeutics shares in Q2 2022, an estimated $103K.
Veritable first reported a position in Gain Therapeutics in Q3 2021 and held it in 3 quarters.
Veritable's Gain Therapeutics position peaked at $187K in Q3 2021.
16 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2022.

Based on Veritable's 13F filing for Q2 2022, filed 15 Aug 2022.